

# New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia

Saturday, April 27, 2019  
7:00 AM - 3:30 PM

Jointly  
provided by:



## Educational Grants

Novartis Pharmaceuticals Corporation  
Takeda Oncology

For online registration and more information visit:  
[www.cancernetus.com](http://www.cancernetus.com)



**Houston Marriott  
at the  
Texas Medical Center**

6580 Fannin Street  
Houston, TX 77030  
Phone: (713) 796-0080

## REGISTRATION FORM

### New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia

First Name \_\_\_\_\_ Middle Initial \_\_\_\_ Last Name \_\_\_\_\_

Physician  Pa-C  NP  PhD  Pharmacist  Industry  Nurse  Other

Mailing Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

Email \_\_\_\_\_

Speciality \_\_\_\_\_

Fax registration to: 443-267-0016

Mail registration to:  
860 Hebron Pkwy, Suite 1104  
Lewisville, TX 75057

Check box to receive information  
about Live and Webcast programs.  
You can unsubscribe at any time.

## Registration Fee (Registration fee includes buffet breakfast, lunch and syllabus book.)

	Early Registration Fee - Up to 4/15/19	Discounted Registration Fee - 4/16/19 - 4/22/19	Regular Registration Fee - 4/23/19 - 4/27/19
<input type="checkbox"/> Physicians	\$100.00	\$130.00	\$160.00
<input type="checkbox"/> Nurses, Nurse Practitioners, Physician Assistants	\$ 75.00	\$ 95.00	\$115.00
<input type="checkbox"/> Pharmacists, Fellows	\$ 75.00	\$ 95.00	\$115.00
<input type="checkbox"/> Industry †	\$350.00	\$400.00	\$450.00

† Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

**No refund; substitution is allowed.**

Payment may be made:  MC  Visa  Discover  Check

Credit Card Number \_\_\_\_\_ Expiration Date \_\_\_\_\_

Name and address (as given on the monthly credit card statement) \_\_\_\_\_

Pharmacist e-profile NABP#: \_\_\_\_\_ Pharmacist DOB (MMDD): \_\_\_\_\_

Signature \_\_\_\_\_

Register online at [www.cancernetus.com](http://www.cancernetus.com) Please make checks payable to **CancerNet, LLC**. Mail checks to CancerNet, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057 To reserve your place for the meeting, please complete the registration form and fax it to 443-267-0016. For questions, please call Brian Waggoner at 972-459-5222 or E-mail: [brianw@cancernetus.com](mailto:brianw@cancernetus.com)

## Faculty

### **Jan A. Burger, MD, PhD**

Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

### **Naval G. Daver, MD**

Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

### **Courtney DiNardo, MD**

Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

### **Elias Jabbour, MD**

Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

### **William G. Wierda, MD, PhD**

Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

## **New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia**

**Saturday, April 27, 2019**

**Houston Marriott at the Texas Medical Center**

6580 Fannin Street, Houston, TX 77030

Phone: (713) 796-0080

### **Statement of Need / Program Overview**

This symposium is intended to improve care of patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML) by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

### **Target Audience**

This symposium is directed primarily to hematologists/oncologists, physician assistants, nurse practitioners, registered nurses, pharmacists and fellows in training interested in new development in ALL, CLL, AML and CML. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

### **Learning Objectives**

Describe the alterations in cytogenetic, molecular abnormalities, NOTCH1, CRLF2 mutations, epigenetic markers in the diagnosis and treatment of patients with acute lymphoblastic leukemia (ALL)

Identify the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with ALL

Assess the prognostic markers, risk stratification and their impact on clinical practice of patients with chronic lymphocytic lymphoma (CLL)

Identify and apply individualized treatment strategies based on current and emerging novel therapies for CLL

Describe the alterations in driver mutations revealing molecular subgroups leading to disease classification and prognostic stratification in acute myeloid leukemia (AML)

Recognize how compound genotypes are related to clinical outcomes in AML patients treated with novel agents

Evaluate the first line therapy options for chronic myeloid leukemia (CML) in chronic phase

Identify response assessment and management of tyrosine kinase inhibitors resistance in the treatment of CML

Recognize the time-based response milestones and monitoring in patients with CML

# AGENDA

## New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia

7:00 AM	Onsite Registration and Buffet Breakfast	
7:55 AM	Opening Remarks	William G. Wierda, MD, PhD
<b>ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)</b>		
8:00 AM	Pretest – Case Vignettes	TBD / Elias Jabbour, MD
8:15 AM	Overview of Diagnosis Based on Cytogenetic and Molecular Abnormalities in Patients with ALL	TBD
8:45 AM	Novel Therapies for adolescents and young adults (AYA), Philadelphia-positive and Philadelphia-negative Relapsed/Refractory Patients with ALL	Elias Jabbour, MD
9:15 AM	Posttest – Case Vignettes	TBD / Elias Jabbour, MD
9:30 AM	BREAK	
<b>ACUTE MYELOID LEUKEMIA (AML)</b>		
9:45 AM	Pretest – Case Vignettes	Naval G. Daver, MD / Courtney DiNardo, MD
10:00 AM	Overview of Disease Classification and Prognostic Stratification in Patients with AML	Naval G. Daver, MD
10:30 AM	Treatment Options with Novel IDH1/2, FLT3 and CD33 Targeted Agents in Genomic Subgroups of AML	Courtney DiNardo, MD
11:00 AM	Posttest – Case Vignettes	Naval G. Daver, MD / Courtney DiNardo, MD
<b>CHRONIC MYELOID LEUKEMIA (CML)</b>		
11:15 AM	Pretest – Case Vignettes	TBD / Elias Jabbour, MD
11:30 AM	Response Assessment and Management of TKIs Resistance in the Management of CML	TBD
12:00 PM	LUNCH	
1:00 PM	Understanding of Time-based Response Milestones and Monitoring in Patients with CML	Elias Jabbour, MD
1:30 PM	Posttest – Case Vignettes	TBD / Elias Jabbour, MD
<b>CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)</b>		
1:45 PM	Pretest – Case Vignettes	Jan A. Burger, MD, PhD / William G. Wierda, MD, PhD
2:00 PM	Emerging Prognostic Markers and Risk Stratification in Treatment Decision Making for Patients with CLL	Jan A. Burger, MD, PhD
2:30 PM	BREAK	
2:45 PM	Changing the Treatment Paradigm for CLL: Chemo-immunotherapy versus Targeted Therapy	William G. Wierda, MD, PhD
3:15 PM	Posttest – Case Vignettes	Jan A. Burger, MD, PhD / William G. Wierda, MD, PhD
3:30 PM	Closing Remarks and Adjourn	William G. Wierda, MD, PhD

### Physician Continuing Education

#### Accreditation Statement:



This activity has been planned and implemented in accordance with the accreditation requirements and the policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health and CancerNet, LLC. The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.

#### Credit Designation:

The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this educational activity for a maximum of 6.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



#### Nursing and Pharmacist Continuing Education

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

*Credit Designation Statement* – Amedco LLC designates this live activity for a maximum of 6.00 contact hours for nurses and 6.00 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity. Event UAN: JA4008163-9999-19-015-L04-P

#### Instructions for Claiming AMA PRA Category 1 Credit(s) (Physicians, PAs and NPs):

- In order to receive credit, all attendees must sign-in at the beginning of the activity, submit a completed evaluation and claim credit online through BSWH.md/cmecredit. Instructions on how to complete the evaluation and claiming credit online are included in program handouts.

#### Participant Requirements for Credit (Nurses and Pharmacists):

- Participants must fully attend all sessions as well as turn in a completed signature verification form (No partial credit will be given). Participants can earn Continuing Education credits for this program by electronically logging onto the website for;
- Nurses and Pharmacists at <http://can.cmecertificateonline.com> and completing the evaluation. After completion of the evaluation, you can print your certificate immediately and one is emailed to you. **NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.**
- All participant names will be checked against program attendance sheets for verification of attendance.

**Disclosure & Evaluation:** All participants will have the opportunity to evaluate the educational session and presenter as well as the ability to identify their future educational needs. Disclosure will be made on the day of the program regarding any relevant financial relationship an individual may have with a commercial interest organization.

**Participants may reserve guest rooms by calling (713) 796-0080**



860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057  
Tel: (972) 459-5222 · Fax: (443) 267-0016  
[www.cancernetus.com](http://www.cancernetus.com)